FLT3-ITD
About
Gene context: FLT3
Biomarker Type: Somatic Variant
Present: True
Chromosome: 13
Variant Annotation: Internal Tandem Duplication (ITD)
Requires Oncogenic: True
Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
Therapeutic response
Precision oncology relationships for therapeutic response involving this biomarker.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (1) | FLT3-ITD | Acute Lymphoid Leukemia | Gilteritinib | |
| EMA (1) FDA (1) | FLT3-ITD | Acute Myeloid Leukemia | Cytarabine, Daunorubicin, Midostaurin | |
| EMA (1) | FLT3-ITD | Acute Myeloid Leukemia | Gilteritinib | |
| EMA (1) FDA (1) | FLT3-ITD | Acute Myeloid Leukemia | Quizartinib | |
| EMA (1) FDA (1) | FLT3-ITD | Acute Myeloid Leukemia | Cytarabine, Daunorubicin, Quizartinib | |
| EMA (1) FDA (1) | FLT3-ITD | Acute Myeloid Leukemia | Cytarabine, Idarubicin, Quizartinib |